SCHEMBL490913

SCHEMBL490913

O=C(Nc1ccc(S(=O)(=O)c2ccc([N+](=O)[O-])cc2)cc1)c1cc(Cl)ccc1NS(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC10A6 Q3KNW5 3/20 0.64
SLC10A2 Q12908 2/20 0.64
SLC10A1 Q14973 2/20 0.64
GPR27 Q9NS67 4/20 0.53
FLT1 P17948 3/20 0.52
FLT4 P35916 3/20 0.52
KDR P35968 3/20 0.52
KMT2A Q03164 5/20 0.52
MEN1 O00255 4/20 0.52
KDM4E B2RXH2 2/20 0.52
BCL2L1 Q07817 1/20 0.51
KCNA5 P22460 1/20 0.51
AVPR2 P30518 1/20 0.50
ALDH1A1 P00352 1/20 0.50
CYP3A4 P08684 1/20 0.50
HPGD P15428 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
MAPT P10636 1/20 0.49
HTT P42858 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL491757 0.91 SLC10A6 (0.61) SLC10A6SLC10A2SLC10A1GPR27FLT1
SCHEMBL6860323 0.90 SLC10A6 (0.59) SLC10A6SLC10A2SLC10A1GPR27FLT1
SCHEMBL6754585 0.88 SLC10A6 (0.81) SLC10A6SLC10A2SLC10A1GPR27KMT2A
SCHEMBL6862956 0.85 SLC10A6 (0.62) SLC10A6SLC10A2SLC10A1GPR27FLT1
SCHEMBL5111951 0.85 P2RX1 (0.65) SLC10A6SLC10A2SLC10A1GPR27FLT1
SCHEMBL492154 0.83 KMT2A (0.69) SLC10A6SLC10A2SLC10A1KMT2AMEN1
SCHEMBL6760783 0.83 SLC10A6 (0.74) SLC10A6SLC10A2SLC10A1GPR27KMT2A
SCHEMBL17891629 0.83 SLC10A6 (0.82) SLC10A6SLC10A2SLC10A1GPR27KMT2A
SCHEMBL5125625 0.82 KCNMA1 (0.71) SLC10A6SLC10A2SLC10A1KDRKMT2A
SCHEMBL491625 0.82 SLC10A6 (0.72) SLC10A6SLC10A2SLC10A1GPR27KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541410-B2 Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2013-09-24 US disclosed
US-20120108573-A1 SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM SANOFI-AVENTIS DEUTSCHLAND GMBH 2012-05-03 US disclosed
US-8106213-B2 For example, 2-(4-chloro-phenylsulfonylamino)-4,5-dimethoxy-N-(4-(thiomorpholine-4-sulfonyl)-phenyl)-benzamide; for therapy and prophylaxis of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2012-01-31 US disclosed
US-20080096936-A1 Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them TELEVOX SOFTWARE, INCORPORATED 2008-04-24 US disclosed
CN-1332943-C Sulfur-substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them AVENTIS PHARMACEUTICALS AG (DE) 2007-08-22 CN disclosed
EP-1614678-A2 Sulfur substituted sulfonylaminocarboxylic acid N-heteroarylamides, their preparation, their use and pharmaceutical preparations comprising them Sanofi-Aventis Deutschland GmbH (DE) 2006-01-11 EP disclosed
EP-1095016-B1 SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM SANOFI AVENTIS DEUTSCHLAND (DE) 2005-11-09 EP disclosed
US-6881735-B2 Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-04-19 US disclosed
US-20020061887-A1 Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH 2002-05-23 US disclosed
US-6335334-B1 HYPERTENSIVE AGENTS, ANTICOAGULANTS; CARDIOVASCULAR AND SEXUAL DISORDERS, ANGINA PECTORIS, AND ATHEROSCLEROSIS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-01-01 US disclosed
CN-1308606-A Sulfur-substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them AVENTIS PHARMACEUTICALS AG (DE) 2001-08-15 CN disclosed
EP-1095016-A1 SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM Aventis Pharma Deutschland GmbH (DE) 2001-05-02 EP disclosed
WO-2000002851-A1 SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108573-A1 SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM GUCY1A1, GUCY1B1, GUCY1A2 SLC10A6 1785/4885SLC10A2 2103/4885SLC10A1 1054/4885
US-20020061887-A1 Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them GUCY1A1, GUCY1B1, GUCY1A2 SLC10A6 2557/4885SLC10A2 2365/4885SLC10A1 1586/4885
US-20080096936-A1 Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them GUCY1A1, GUCY1A2, GUCY1B1 SLC10A6 1841/4885SLC10A2 2189/4885SLC10A1 1109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.